VENETOCLAX
Information current as at: 1 August 2025
The pharmaceutical company has withdrawn their submission for this medicine prior to the medicine being considered at the PBAC meeting.
PBAC meeting date: March 2022
Submission Details
- Brand name:
-
- Venclexta®
- Pharmaceutical company:
- Abbvie Pty Ltd
- Condition/indication:
(therapeutic use) -
- Chronic lymphocytic leukaemia or small lymphocytic lymphoma
- PBAC Submission type:
- Change to listing (–)
- Comment:
- --
- Related medicines:
- --
Progress Details
-
Submission received for: - March 2022 PBAC meeting
-
Opportunity for consumer comment: - Not applicable
-
PBAC meeting: - Not applicable
-
PBAC outcome published: - Not Applicable (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a506
Page last updated: 30 June 2025